^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/28/2020
    Excerpt:
    Pediatric Hodgkin Lymphoma...Re-Induction Therapy Options...Brentuximab Vedotin+nivolumab...Hodgkin lymphoma: Second-line options…Brentuximab vedotin + nivolumab